成都欧林生物科技股份有限公司关于筹划发行 H股股票并在香港联合交易所有限公司上市的 提示性公告

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its international strategy, increase its global visibility, and optimize its capital structure [1][2]. Group 1 - The company is currently discussing the details of the H-share listing with relevant intermediaries, and specific details have not yet been finalized [2]. - The H-share listing process will require approval from the company's board and shareholders, as well as regulatory approvals from the China Securities Regulatory Commission, the Hong Kong Stock Exchange, and the Securities and Futures Commission of Hong Kong [2]. - The company will fulfill its information disclosure obligations in accordance with relevant laws and regulations as the H-share listing progresses [2].